Cancer Gene Therapy Market Sales Revenue Opportunity Report

The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.

Download Report:

https://www.kuickresearch.com/report-Cancer-Gene-Therapy-Market-Analysis.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Cancer Gene Therapy Market Analysis" Table of Contents

1. Introduction to Gene Therapy
1.1 History of Gene Therapy
1.2 Vectors of Gene Therapy

2. Global Gene Therapy Market
2.1 Market Overview
2.2 Emerging Trends in Gene Therapy

3. Significance of Cancer Therapeutics in Gene Therapy

4. Current Applications of Gene Therapy to Cancer Treatment
4.1 Cancer Treatments Currently Available
4.2 Approaches to Cancer Gene Therapy
4.3 Gene Therapy Used in Cancer Treatment
4.4 Methods of Inserting Genes into Cancer Patients

5. Cancer Gene Therapy Market Dynamics
5.1 Favorable Parameters for Cancer Gene Therapy
5.2 Issued Involved with Application of Gene Therapy in Cancer Patients
5.3 Cancer Gene Therapy Clinical Insight

6. Regulatory Scenario for Gene Therapy Market
6.1 EU
6.2 US

7. Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications
7.1 Unknown Phase
7.2 Research
7.3 Preclinical
7.4 Phase I/II
7.5 Phase II
7.6 Phase III

8. Marketed Cancer Gene Therapy Drugs

9. Suspended & Discontinued Cancer Gene Therapy Drug Pipeline
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended

10. Competitive Landscape
10.1 Advantagene
10.2 BioCancell
10.3 Celgene
10.4 Cell Genesys
10.5 Epeius Biotechnologies
10.6 GenVec
10.7 Introgen Therapeutics
10.8 MultiVir
10.9 ZIOPHARM Oncology
10.10 Shenzhen SiBiono GeneTech

Figure 3-1: Gene Therapy by Indication
Figure 5-1: Favorable Parameters for Cancer Gene Therapy
Figure 5-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
Figure 5-3: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number of Drugs), 2014
Figure 5-4: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-5: Suspended Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-6: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-7: Discontinued Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Figure 5-8: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
Figure 5-9: No Development Reported Cancer Gene Therapy Drug by Phase (Number of
Drugs), 2014

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.